Within the first 100 days of the current US Administration, there have been a series of changes in the US that will impact the pharmaceutical industry.
To date, key outcomes have included:
- Leadership changes across the Department of Health and Human Services (HHS)
- Major cuts across key departments and health programs
- Additional regulations that may curb investments
- Introduction of a reciprocal tariff framework
- Significant tariffs on strategic sectors such as steel, aluminum, and automotive and potential tariffs on pharmaceuticals
- Heightened tensions between the US and China
Scope
- This report examines the transition of the 47th U.S. Administration toward a protectionist trade policy during its first 100 days.
Table of Contents
- Introduction
- Impact of Geopolitical Changes and Macroeconomics on Pharma
- Leadership: Key Departmental Changes Will Have Significant Impact on Pharma Industry and Patients
- Reduced Funding and Staff Cuts: ~10,000 Employees Fired Across Healthcare Departments and $250 Million in Cuts in NIH Funding
- New Regulations and Policies
- China Impact and Innovation Boost
- Tariffs
- Revitalization of the Biotech Industry to Support Innovation
- About the Analyst
- Contact the Publisher
